St. Jude Children's Research Hospital

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1962-01-01

Employees: -

Market Cap: -

Website: http://www.stjude.org/

Clinical Trials

Evaluation of the Safety of a Polyvalent Virus in Healthy Adults

Phase 1

Completed

Conditions: HIV Infection
Human Immunodeficiency Virus

Interventions: Biological: PolyEnv1 vaccine

First Posted Date: 2005-09-16

Last Posted Date: 2011-09-29

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 18

Registration Number: NCT00187044

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors

Phase 1

Completed

Conditions: Abdominal Neoplasms
Pelvic Neoplasms

Interventions: Drug: Optison

First Posted Date: 2005-09-16

Last Posted Date: 2011-09-20

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 14

Registration Number: NCT00186953

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Study for Treatment of Cancer in Children With Ataxia-telangiectasia

Not Applicable

Completed

Conditions: Ataxia-Telangiectasia

Interventions: Drug: vinblastine, vincristine, prednisone, daunorubicin
Drug: doxorubicin, methotrexate, cyclophosphamide, L-asparaginase
Drug: etoposide, cytarabine, mercaptopurine
Drug: dexamethasone, procarbazine
Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy

First Posted Date: 2005-09-16

Last Posted Date: 2015-08-27

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 6

Registration Number: NCT00187057

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Phase 3

Terminated

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase
Drug: L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine

First Posted Date: 2005-09-16

Last Posted Date: 2011-03-30

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 53

Registration Number: NCT00187005

Locations: 🇺🇸
St.Jude Children's Research Hospital, Memphis, Tennessee, United States

Natural Killer (NK) Cell Transplantation for AML

Not Applicable

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2
Procedure: Natural Killer Cell Infusion
Device: CliniMACS System

First Posted Date: 2005-09-16

Last Posted Date: 2014-06-19

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 49

Registration Number: NCT00187096

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Acute Lymphoblastic Leukemia
Lymphoma, Lymphoblastic

Interventions: Drug: Etoposide, cytarabine, vincristine, dexamethasone
Drug: methotrexate, teniposide, PEG-asparaginase
Drug: mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine
Drug: L-asparaginase, erwinia asparaginase
Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy
Procedure: Hematopoietic Stem Cell Transplant
Procedure: Natural Killer (NK) Cell Transplant

First Posted Date: 2005-09-16

Last Posted Date: 2017-07-28

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 47

Registration Number: NCT00186875

Locations: 🇺🇸
Rady Children's Hospital and Health Center, San Diego, California, United States
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

A Study to Assess the Safety of Live Intranasal Sendai Virus Vaccine in Children and Toddlers

Phase 1

Suspended

Conditions: Parainfluenza
Respiratory Viral Infections

Interventions: Biological: Sendai virus vaccine

First Posted Date: 2005-09-16

Last Posted Date: 2024-02-13

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 54

Registration Number: NCT00186927

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors

Phase 1

Completed

Conditions: Tumors
Rhabdomyosarcoma
Sarcoma, Soft Tissue
Brain Tumors

Interventions: Drug: Everolimus

First Posted Date: 2005-09-16

Last Posted Date: 2015-03-04

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 41

Registration Number: NCT00187174

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Stromal Therapy of Osteodysplasia After Allogeneic Bone Marrow Transplantation

Phase 1

Completed

Conditions: Osteodysplasia

Interventions: Biological: Marrow stromal cell infusion

First Posted Date: 2005-09-16

Last Posted Date: 2015-03-04

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 8

Registration Number: NCT00186914

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Irinotecan, ZD1839, Vincristine, Cefixime, Cefpodoxime.

First Posted Date: 2005-09-16

Last Posted Date: 2017-04-26

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 34

Registration Number: NCT00186979

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy